Ayman Madi

2.0k total citations
26 papers, 560 citations indexed

About

Ayman Madi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Ayman Madi has authored 26 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Ayman Madi's work include Colorectal Cancer Treatments and Studies (18 papers), Genetic factors in colorectal cancer (7 papers) and Gastric Cancer Management and Outcomes (7 papers). Ayman Madi is often cited by papers focused on Colorectal Cancer Treatments and Studies (18 papers), Genetic factors in colorectal cancer (7 papers) and Gastric Cancer Management and Outcomes (7 papers). Ayman Madi collaborates with scholars based in United Kingdom, United States and Germany. Ayman Madi's co-authors include Angela Meade, Richard Adams, Tim Maughan, Richard Kaplan, David J. Fisher, Richard H. Wilson, Harpreet Wasan, Michel Seymour, Sarah Kenny and Jeremy P. Cheadle and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

Ayman Madi

25 papers receiving 546 citations

Peers

Countries citing papers authored by Ayman Madi

Since Specialization

Citations

This map shows the geographic impact of Ayman Madi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ayman Madi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ayman Madi more than expected).

Fields of papers citing papers by Ayman Madi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ayman Madi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ayman Madi. The network helps show where Ayman Madi may publish in the future.

Co-authorship network of co-authors of Ayman Madi

This figure shows the co-authorship network connecting the top 25 collaborators of Ayman Madi. A scholar is included among the top collaborators of Ayman Madi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ayman Madi. Ayman Madi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of the introduction of primary G-CSF prophylaxis to the FLOT chemotherapy regimen 2019 ·Annals of Oncology ·(unknown), (unknown), Helen Wong, (unknown), Ayman Madi	1
2	Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy 2018 ·European Journal of Cancer ·Ayman Madi, David J. Fisher, Tim Maughan, James Colley, Angela Meade, Julie Maynard, (unknown), Harpreet Wasan, Richard Adams, Shelley Idziaszczyk, Rebecca Harris, Richard Kaplan, Jeremy P. Cheadle	28
3	Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab 2017 ·Journal of Medical Genetics ·Ayman Madi, David J. Fisher, Tim Maughan, James Colley, Angela Meade, Sabine Tejpar, (unknown), Julie Maynard, (unknown), Harpreet Wasan, Richard Adams, Shelley Idziaszczyk, Rebecca Harris, Richard Kaplan, Jeremy P. Cheadle	4
4	On the Improvement of Cyclomatic Complexity Metric 2015 ·Ayman Madi, (unknown), Seifedine Kadry	14
5	Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial 2014 ·The Lancet Oncology ·Harpreet Wasan, Angela Meade, Richard Adams, Richard H. Wilson, Cheryl Pugh, David J. Fisher, (unknown), Ayman Madi, Bruce Sizer, C. Lowdell, Gary Middleton, Rachel Butler, Richard Kaplan, Tim Maughan	83
6	Comprehensive pharmacogenetic profiling of advanced colorectal cancer. 2013 ·Journal of Clinical Oncology ·Ayman Madi, David J. Fisher, Tim Maughan, James Colley, Angela Meade, Julie Maynard, (unknown), Harpreet Wasan, Richard Adams, Shelley Idziaszczyk, Rebecca Harris, Laura Nichols, Richard Kaplan, Jeremy P. Cheadle	2
7	A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors 2012 ·Cancer Chemotherapy and Pharmacology ·Ruth Plummer, Ayman Madi, (unknown), Heike Richly, (unknown), Stephen D. Rubin, Howard Ball, Steve Weller, Jeffrey Botbyl, D. Gibson, M. E. Scheulen	25
8	Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial 2012 ·British Journal of Cancer ·Ayman Madi, David J. Fisher, Richard H. Wilson, Richard Adams, Angela Meade, Sarah Kenny, Laura Nichols, Michel Seymour, Harpreet Wasan, Richard Kaplan, Tim Maughan	33
9	A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer. 2012 ·Journal of Clinical Oncology ·(unknown), Ruth Plummer, T.R. Jeffry Evans, (unknown), David Alan Anthoney, (unknown), Ayman Madi, (unknown), Claire Johnston, David Carter, Larisa Reyderman, Prashanth Gopalakrishna, J. Wanders, Christopher Twelves	6
10	Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): Results of the two-arm phase II randomized MRC COIN-B trial. 2012 ·Journal of Clinical Oncology ·Harpreet Wasan, Richard Adams, Richard H. Wilson, Cheryl Pugh, David J. Fisher, Ayman Madi, Bruce Sizer, Rachel Butler, Angela Meade, Tim Maughan	10
11	Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial 2011 ·The Lancet Oncology ·Richard Adams, Angela Meade, Michel Seymour, Richard H. Wilson, Ayman Madi, David J. Fisher, Sarah Kenny, (unknown), Elizabeth Hodgkinson, (unknown), P. Rogers, Harpreet Wasan, Stephen Falk, Simon Gollins, Tamas Hickish, E.M. Bessell, David Propper, Megan Kennedy, Richard Kaplan, Tim Maughan	177
12	THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS 2010 ·Annals of Oncology ·(unknown), Richard Adams, (unknown), Michel Seymour, Robert Wilson, Angela Meade, David I. Fisher, Ayman Madi, Jeremy P. Cheadle, Raphael Kaplan	3
13	THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL 2010 ·Annals of Oncology ·Ayman Madi, (unknown), Richard Adams, Michel Seymour, Angela Meade, J Cassidy, (unknown), Sarah Kenny, Richard Kaplan, (unknown)	2
14	Fulminant hepatic failure in a patient with advanced extragonadal germ cell tumour 2010 ·BMJ Case Reports ·Alastair L. Young, Ayman Madi, Darren Treanor, (unknown), Peter J. Selby, John Chester	1
15	Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial. 2010 ·Journal of Clinical Oncology ·Tim Maughan, Richard Adams, Christopher G. Smith, Michel Seymour, Richard H. Wilson, Angela Meade, David I. Fisher, Ayman Madi, Jeremy P. Cheadle, Raphael Kaplan, (unknown)	34
16	ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS 2009 ·Annals of Oncology ·(unknown), (unknown), (unknown), Michel Seymour, Robert Wilson, Angela Meade, David I. Fisher, Ayman Madi, Sarah Kenny, Harpreet Wasan, Pauline Rogers, Elizabeth Hodgkinson, Bharat Jasani, Jeremy P. Cheadle, Raphael Kaplan	1
17	Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience 2009 ·British Journal of Cancer ·(unknown), Richard Adams, Angela Meade, Ayman Madi, David J. Fisher, (unknown), Sarah Kenny, Richard Kaplan, Tim Maughan	52
18	6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN) 2009 ·European Journal of Cancer Supplements ·(unknown), Richard Adams, Charlotte G. Smith, Michel Seymour, Robert Wilson, Angela Meade, David I. Fisher, Ayman Madi, Jeremy P. Cheadle, Raphael Kaplan	34
19	The activated partial thromboplastin time in early diagnosis of myocardial infarction 2001 ·Blood Coagulation & Fibrinolysis ·Ayman Madi, (unknown), Haq Nawaz, David L. Katz	14
20	Peri-operative aspirin can prevent post-operative ischemia and thrombosis 2000 ·Medical Hypotheses ·Ayman Madi, (unknown), Haq Nawaz, David L. Katz	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact